JAC Advance Access published online on July 30, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl320
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medical Microbiology and Hygiene, University Hospital, Ulm, Germany
* To whom correspondence should be addressed. Objectives: Recent studies have shown a beneficial impact of fluoroquinolones on infection-related morbidity and mortality for patients with haematological malignancies during neutropenia. Among the fluoroquinolones moxifloxacin currently provides one of the broadest spectra of antibacterial activity and may be suitable for prophylaxis during neutropenia. Patients and methods: In this controlled before and after observational study, moxifloxacin chemoprophylaxis was used during prolonged neutropenia in haemato-oncological patients (period 2; 282 episodes). Data were compared with two periods with levofloxacin prophylaxis, one preceding period (period 1; 399 episodes) and a post-observational period (period 3; 53 episodes). Endpoints for evaluation were the rates of Gram-negative and Gram-positive bacteraemia and infection-related mortality. Results: We found similar survival rates as compared with levofloxacin. The rate of Gram-negative bacteraemia was higher during prophylaxis with moxifloxacin (11%) when compared with levofloxacin (6% for period 1 and 6% for period 3). In addition we observed a marked increase in diarrhoea associated with Clostridium difficile toxin A (CDAD) after a formula change from levofloxacin to moxifloxacin (attack rate 6% versus 33%). A decrease was attained after changing back to levofloxacin and reinforcing hygienic measures (13%). Conclusions: During moxifloxacin prophylaxis, we observed a significantly increased incidence of Gram-negative bacteraemia and CDAD. Careful attention must be paid not to trade the particularly beneficial effects of fluoroquinolones in the neutropenic setting for such disadvantageous effects. Until further data are obtained, caution is warranted when applying fluoroquinolones with high anaerobic activity in the neutropenic setting.
Received June 1, 2006
Revised July 5, 2006
Accepted July 12, 2006
Brief report
Moxifloxacin prophylaxis in neutropenic patients
H. von Baum 1, A. Sigge 1, M. Bommer 2, W. V. Kern 3, R. Marre 1, H. Döhner 2, P. Kern 4, and S. Reuter 5 *
2 Department of Internal Medicine III, University Hospital, Ulm, Germany
3 Center for Infectious Diseases and Travel Medicine, University Hospital, Freiburg, Germany
4 Section of Infectious Diseases and Clinical Immunology, University Hospital, Ulm, Germany
5 Department of Internal Medicine III, University Hospital, Ulm, Germany; Section of Infectious Diseases and Clinical Immunology, University Hospital, Ulm, Germany
S. Reuter, E-mail: stefan.reuter{at}uniklinik-ulm.de
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J Mehlhorn and D. A Brown Safety Concerns with Fluoroquinolones Ann. Pharmacother., November 1, 2007; 41(11): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Adams, M. M. Riggs, and C. J. Donskey Effect of Fluoroquinolone Treatment on Growth of and Toxin Production by Epidemic and Nonepidemic Clostridium difficile Strains in the Cecal Contents of Mice Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2674 - 2678. [Abstract] [Full Text] [PDF]
|
|